Michael A. Malfatti
Biosciences and Biotechnology Division
Lawrence Livermore National Laboratory
7000 East Avenue, L-452
Ph.D., Pharmacology/Toxicology, University of California, Davis, 2005
M.A., Biological Science, California State University, San Jose, 1992
B.S., Biological Science, California State University, San Jose, 1989
Toxicology, Pharmacology, Biochemistry, Biomedical applications of accelerator mass spectrometry.
My research includes characterizing the low-dose pharmacokinetic, metabolism, and tissue distribution properties of toxicants and potential drug leads using accelerator mass spectrometry in an effort to understand their mechanisms of action. We are also using a pharmacogenomics approach to understand inter-individual susceptibility to adverse drug reactions. We are also studying the toxic and/or carcinogenic effects of small molecules in subcellular, cellular and animal models to determine how these effects relate to human cancer susceptibility. We are also developing a novel platform, using nanolipoprotein particles, to enhance the metabolism and elimination of chemical toxicants.
1. He W, Luo J, Bourguet F, Xing L, Yi SK, Gao T, Blanchette C, Henderson PT, Kuhn E, Malfatti M, Murphy WJ, Cheng RH, Lam KS, Coleman MA. (2013) Controlling the diameter, monodispersity, and solubility of ApoA1 nanolipoprotein particles using telodendrimer chemistry. Protein Sci. Aug;22(8):1078-86
2. Malfatti, M. A., Palko, H. A., Kuhn, E. A., Turteltaub, K. W. (2012) Determining the pharmacokinetics and long-term biodistribution of SiO2 nanoparticles in vivo using accelerator mass spectrometry. Nano Letters, 12, 5532-5538
3. Neuwirth C, Mosesso P, Pepe G, Fiore M, Malfatti M, Turteltaub K, Dekant W, Mally A. (2012) Furan carcinogenicity: DNA binding and genotoxicity of furan in rats in vivo. Mol Nutr Food Res., 56, 1363-1374.
4. Paul T. Henderson, Tao Li, Miaoling He, Hongyong Zhang, Michael Malfatti, Peter Grimminger, Kathryn Dannenberg, Ralph W. de Vere White, Kenneth W. Turteltaub, Chong-xian Pan (2011) A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. International Journal of Cancer, 129, 1425-1434.
5. Sisi Wang, Hongyong Zhang, Michael Malfatti, Ralph de Vere White, Primo Lara, Kenneth Turteltaub, Paul Henderson,Chong-xian Pan (2010). Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chemical Research in Toxicology, 23, 1653-1655.
6. Chen, C., Ma, X., Malfatti, M., Krausz, K., Kimura, S., Felton, J., Idle, J., and Gonzalez, F. (2007) A Comprehensive Investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) Metabolism in the Mouse Using a Multivariate Data Analysis Approach. Chemical Research in Toxicology, 20, 531-542.
7. Felton, J.S. and Malfatti, M.A. (2006) What do diet-induced changes in phase I and II enzymes tell us about prevention from exposure to heterocyclic amine? Journal of Nutrition, 136, 2683S-2684S.
8. Malfatti, M.A., Dingley, K.H., Nowell, S., Ubick, E.A., Mulakken, N., Nelson, D., Lang, N.P., Felton, J.S., and Turteltaub, K.W. (2006) The urinary metabolite profile of the dietary Carcinogen PhIP is predictive of colon DNA adducts after a low dose exposure in humans. Cancer Research, 66, 10541-10547.
9. Malfatti, M.A., Ubick E.A. and Felton, J.S. (2005) The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. Carcinogenesis, 26, 2019-2028.
10. Malfatti, M.A., Wu, R.W., and Felton, J.S. (2005) The Effect of UDP-glucuronosyltransferase 1A1 expression on the Mutagenicity and Metabolism of the Cooked-Food Carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in CHO Cells. Mutation Research, 570, 205-214.